Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. These lesions even worsened for some weeks after interruption of cabergoline, which may possibly be related to the prolonged action of this drug. Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.
Frans
E
E
Department of Medicine, University Hospitals, Catholic University Leuven, Belgium.
Dom
R
R
Demedts
M
M
D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010996:Pleural Effusion / Q000139:chemically induced
D015259:Dopamine Agents; D004873:Ergolines; D001971:Bromocriptine; D000077465:Cabergoline